Morgan Stanley maintains a "overweight" rating on GUSHENGTANG(02273) with a target price of 62 Hong Kong dollars.
Currently, private hospitals are not required to participate in volume-based procurement. The company expects the group to achieve a revenue growth of over 20% this year, with a profit increase of over 25%.
Morgan Stanley released a research report stating that they are maintaining a "buy" rating for GUSHENGTANG (02273) with a target price of 62 Hong Kong dollars. Currently, private hospitals are not required to participate in volume-based procurement. The bank expects the group to achieve revenue growth of over 20% this year, with profit growth expected to be over 25%.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
